natgillin/translations-raw huggingface dataset:
Additionally, as the IV valproate formulations will likely be administered by different HCPs than the usual treating physicians, having a HCP guide in place for these products is crucial and therefore such HCP guide will also be provided to prescribers of IV formulation of valproate containing products. 
Ker bodo farmacevtske oblike valproata za injiciranje najverjetneje dajali drugi zdravstveni delavci in ne lečeči zdravniki kot običajno, je poleg tega za zdravstvene delavce ključna vzpostavitev njim namenjenega vodnika za ta zdravila, zato bo a voljo tudi zdravstvenim delavcem, ki predpisujejo farmacevtske oblike zdravil za injiciranje, ki vsebujejo valproat.
Therefore, it is considered that the patient card is not required for injectable formulations products containing valproate and related substances. 
Zato velja, da za farmacevtske oblike zdravil za injiciranje, ki vsebujejo valproat in sorodne snovi, kartica za bolnika ni potrebna.
The PRAC agrees that more research is necessary to evaluate whether 
Odbor PRAC se strinja, da je za oceno, ali valproat res
A pregnancy prevention programme will be implemented accordingly to prevent valproate exposure during pregnancy given that significant risk of lifelong harm is associated with its use. 
Ker je z uporabo valproata povezano znatno tveganje vseživljenjskih poškodb, bo ustrezno uveden program za preprečevanje nosečnosti, da se prepreči izpostavljenost valproatu med nosečnostjo.
In view of the above, the Committee considers that the benefit-risk balance of medicinal products containing substances related to valproate remains favourable subject to the agreed conditions to the marketing authorisations, and taking into account the agreed amendments to the product information and other risk minimisation measures. 
Glede na navedeno odbor meni, da je ob upoštevanju dogovorjenih pogojev za dovoljenja za promet z zdravilom ter dogovorjenih sprememb informacij o zdravilu in drugih ukrepov za zmanjševanje tveganj razmerje med tveganji in koristmi zdravil, ki vsebujejo valproatu sorodne snovi, še naprej ugodno.
In addition, the guide should familiarise the prescribers with key actions to mitigate the risks associated with the use of valproate in exposed girls and women by using the patient guide and the risk acknowledgment form. 
Poleg tega mora vodnik prek vodnika za bolnike in obrazca za potrditev seznanjenosti s tveganjem seznaniti predpisovalce s ključnimi dejavniki za zmanjševanje tveganj, povezanih z uporabo valproata pri izpostavljenih deklicah in ženskah.
At least annual re-assessment of the need for valproate therapy and consideration of alternative treatment options in female children who experienced menarche and women of childbearing potential should be included. 
Pri deklicah, pri katerih se je že pojavila menarha, in pri ženskah v rodni dobi je treba vključiti vsaj letno ponovno oceno potrebe po zdravljenju z valproatom in premislek o drugih možnostih zdravljenja.
Consequently, the annual risk acknowledgment form is not required for the injectable formulations. 
Ta obrazec zato za farmacevtske oblike za injiciranje ni potreben.
Educational measures are necessary in order to ensure that healthcare professionals and patients are informed about the risks associated with valproate in http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Valproate_and_related_substa nces/human_referral_prac_000032.jsp&mid=WC0b01ac05805c516f pregnant women and women of childbearing potential and on the measures necessary to minimise the risk of exposure on valproate in pregnancy. 
Da bodo zdravstveni delavci in bolniki poučeni o tveganjih, povezanih z uporabo valproata pri nosečih ženskah in ženskah v rodni dobi, ter o ukrepih, ki so potrebni, da je tveganje izpostavljenosti valproatu v nosečnosti čim manjše, so potrebni izobraževalni ukrepi.
A post-authorisation safety study (PASS) using data preferably from existing registries should be performed to further characterise the foetal anticonvulsant syndrome in children with valproate in utero exposure as compared to other anti-epileptic drugs. 
Za dodatno opredelitev antikonvulzivnega sindroma pri plodu pri otrocih, izpostavljenih valproatu in utero, je treba izvesti varnostno študijo po izdaji dovoljenja za promet z zdravilom (PASS), pri čemer je treba po možnosti uporabiti podatke iz obstoječih evidenc.
Usage data from the ongoing joint drug utilisation study (DUS) as well as other data (surveys, national surveys, anecdotal evidence etc.) that have been evaluated in the current referral indicate that valproate is still used by a considerable proportion of WCBP in different MSs for both epilepsy and bipolar disorder indications. 
Podatki o uporabi iz študije o uporabi zdravil (DUS), ki še poteka, in drugi podatki (raziskave, nacionalne raziskave, anekdotični dokazi idr.
solvent: 5 ml 
Vehikel: 5 ml
Powder and solvent for dispersion for injection 
Prašek in vehikel za disperzijo za injiciranje
Immediate Packaging 
velikost pakiranja
1 vial + 1 pre-filled syringe + 1 'MiniSpike' rec. device 
1 viala + 1 napolnjena injekcijska brizga + ločen MiniSpike sistem za prenos
Intravenous use, Intravesical use powder: vial (glass); solvent: pre-filled syringe (glass) 
Prašek: viala (steklo) Vehikel: napolnjena injekcijska brizga (steklo)
MA (EU) number (Invented) name 
Številka EU
Strength Pharmaceutical Form 
zaščiteno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina (koncentracija)
(× 0.85 for female patients) 
(× 0,85 za bolnice)
normally except if you have problems with your kidneys. 
normalno, razen če imate težave z ledvicami.
is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment. 
ni namenjeno temu, da bi ga jemali samo, temveč ga je vedno treba uporabljati v kombinaciji z drugimi zdravili proti epilepsiji.
and certain other medicines may influence each other (interaction). 
in določena druga zdravila imajo lahko medsebojno delovanje (interakcije).
Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made. 
Trenutno razpoložljivi podatki so opisani v poglavjih 4.8, 5.1 in 5.2, vendar ni mogoče dati priporočil o odmerjanju.
+ Supplementary dose is a single additional dose. 
+ Dodaten odmerek je posamičen dopolnilni odmerek.
may be taken with or without food. 
se lahko jemlje s hrano ali brez nje.
B-dul Theodor Pallady nr.50, sector 3, Bucharest, cod 032266 Romania 
B-dul Theodor Pallady nr.50, sector 3, Bucharest, cod 032266 Romunija
until your doctor tells you to stop. 
jemljite, dokler vam zdravnik ne naroči, da nehajte.
You can also report any side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine. 
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
either twice or three times a day. 
morate vzeti dvakrat ali trikrat na dan.
Pregabalin should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). 
Zdravila Pregabalin Zentiva se ne sme uporabljati med nosečnostjo, razen če je nujno potrebno (če koristi za mater jasno prevladajo nad možnim tveganjem za plod).
ANNEX II A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOGA II A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
If you are an elderly patient (over 65 years of age), you should take Pregabalin Zentiva k.s. 
Če ste starejši bolnik (nad 65 let), lahko jemljete zdravilo Pregabalin Zentiva k.s.
• if you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 
• če ste alergični na pregabalin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Elevated liver enzymes* 
Zvišane vrednosti jetrnih encimov*
Angioedema, allergic reaction 
Angioedem, alergična reakcija
CLcr (ml/min) = 
OČkr (ml/min) =
is used to treat long lasting pain caused by damage to the nerves. 
se uporablja za zdravljenje dolgotrajne bolečine, nastale zaradi okvare živcev.
contains lactose monohydrate If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
vsebuje laktozo monohidrat Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics; ATC code: N03AX16. 
Farmakoterapevtska skupina: antiepileptiki, drugi antiepileptiki, oznaka ATC: N03AX16.
Do not store above 30 °C. 
Shranjujte pri temperaturi do 30°C.
1.23 × [140 - age (years)] × weight (kg) serum creatinine (µmol/l) 
1,23 × [140 - starost (leta)] × masa (kg) Kreatinin v serumu (µmol/l)
• lorazepam (used for treating anxiety). 
• lorazepam (uporablja se za zdravljenje tesnobe)
may be taken with oral contraceptives. 
lahko jemljete s peroralnimi kontraceptivi.
is for oral use only. 
je samo za peroralno uporabo.
hard capsules regularly at the same time each day. 
jemljete redno, vsak dan ob istem času.
Women of childbearing potential/Contraception in males and females As the potential risk for humans is unknown, effective contraception must be used in women of child bearing potential. 
Ženske v rodni dobi/kontracepcija pri moških in ženskah Ker možno tveganje za ljudi ni znano, je pri ženskah v rodnem obdobju potrebna uporaba učinkovite kontracepcije.
should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor. 
ne smete uporabljati med nosečnostjo ali dojenjem, razen če vam tako svetuje zdravnik.
Very common: may affect more than 1 in 10 people • Dizziness, drowsiness, headache. 
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov • omotica, zaspanost, glavobol
DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION Date of first authorisation: 27 February 2017. 
Datum prve pridobitve: 27. februar 2017
you notice decreased urination, you should tell your doctor as stopping the medicine may improve this. 
zasledite zmanjšano izločanje urina, morate to povedati zdravniku, saj se lahko s prenehanjem jemanja zdravila stanje izboljša.
These symptoms may occur more commonly or severely if you have been taking pregabalin for a longer period of time. 
Ti znaki se lahko pojavljajo bolj pogosto in z večjo izrazitostjo, če ste pregabalin jemali daljši čas.
SPECIAL STORAGE CONDITIONS Do not store above 30 °C. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30°C.
In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data). 
V spodnji preglednici 2 so po organskih sistemih in pogostnosti navedeni vsi neželeni učinki, ki so se pojavili pri več kot enem bolniku in z incidenco, večjo kot pri placebu (zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov)).
The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day. 
Odmerek, prilagojen vam in vaši bolezni, bo praviloma med 150 mg in 600 mg na dan.
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25 - 30% and a delay in tmax to approximately 2.5 hours. 
Hitrost absorpcije pregabalina se zmanjša, če je uporabljen s hrano; Cmax se zmanjša za približno 25-30 % in tmax se podaljša na približno 2,5 ure.
Printing ink 
Tiskarsko črnilo
25 mg hard capsules are packed into alu/alu (OPA/alu/PVC/alu) blisters as primary packaging. 
25 mg trde kapsule so pakirane v alu/alu (OPA/alu/PVC/alu) pretisnih omotih kot primarni ovojnini.
• A small number of people being treated with anti-epileptics such as pregabalin have had thoughts of harming or killing themselves. 
• Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je pregabalin, so se pojavile misli na samopoškodovanje ali samomor.
Peripheral and central neuropathic pain, epilepsy or generalised anxiety disorder Take the number of hard capsules as instructed by your doctor. 
Periferna in centralna nevropatska bolečina, epilepsija ali generalizirana anksiozna motnja Vzemite toliko trdih kapsul, kot vam je naročil zdravnik.
Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktozene smejo jemati tega zdravila.
You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities. 
Ne vozite, ne upravljajte zapletenih strojev in ne sodelujte pri drugih potencialno nevarnih dejavnostih, dokler ne veste, ali to zdravilo poslabša vašo zmožnost za takšne dejavnosti.
The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)-5methylhexanoic acid]. 
Učinkovina pregabalin je analog gama-aminomaslene kisline [(S)-3-(aminometil)-5- metilheksanojska kislina].
Infections and infestations Common 
Infekcije in okužbe Pogosti
is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults. 
se uporablja za zdravljenje določene oblike epilepsije (parcialnih napadov s sekundarno generalizacijo ali brez nje) pri odraslih.
The safety and efficacy of pregabalin in children below the age of 12 years and in adolescents (12 - 17 years of age) have not been established. 
Varnost in učinkovitost pregabalina pri otrocih, starih do 12 let, in pri mladostnikih (12-17 let) nista bili dokazani.
In accordance with current clinical practice, if pregabalin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and 4.8). 
Če je treba uporabo pregabalina prekiniti, ga je skladno s trenutno klinično prakso, ne glede na indikacijo, priporočljivo zmanjševati postopoma vsaj 1 teden (glejte poglavji 4.4 in 4.8).
is too strong or too weak, talk to your doctor or pharmacist. 
premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
Pregabalin binds to an auxiliary subunit (α2-δ protein) of voltage-gated calcium channels in the central nervous system. 
Pregabalin se veže na pomožno podenoto (beljakovino α2-δ) napetostno odvisnih kalcijevih kanalčkov v osrednjem živčevju.
The AUC was lower by 30% in paediatric patients below a weight of 30 kg due to an increased body weight adjusted clearance of 43% for these patients in comparison to patients weighing ≥ 30 kg. 
Vrednost AUC je bila pri pediatričnih bolnikih, lažjih od 30 kg, za 30 % nižja zaradi povečanega očistka, prilagojenega telesni masi, ki je bil pri teh bolnikih 43 % v primerjavi z bolniki s telesno maso 30 kg ali več.
The degree of dizziness, sleepiness and decreased concentration may be increased if pregabalin is taken together with medicinal products containing: 
Omotica, zaspanost ali zmanjšanje sposobnosti koncentracije se lahko stopnjujejo, če pregabalin vzamemo skupaj z zdravili, ki vsebujejo:
is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. 
je indicirano kot dodatno zdravljenje pri odraslih s parcialnimi napadi, s sekundarno generalizacijo ali brez nje.
• Pregabalin may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. 
• Uporaba pregabalina lahko povzroči zamegljenost ali izgubo vida ali druge spremembe vida, med katerimi so mnoge začasne.
for you to help treat your epilepsy when your current treatment is not controlling your condition. 
kot pomoč za zdravljenje epilepsije, če zdravila, ki jih trenutno uporabljate, bolezni ne obvladujejo.
Lactose intolerance 
Intoleranca za laktozo
is indicated for the treatment of peripheral and central neuropathic pain in adults. 
je indicirano za zdravljenje periferne in centralne nevropatske bolečine pri odraslih.
In clinical trials up to 12 weeks for both peripheral and central neuropathic pain, a reduction in pain was seen by week 1 and was maintained throughout the treatment period. 
V kliničnih preskušanjih v trajanju 12 tednov so tako pri periferni kot centralni nevropatski bolečini že v prvem tednu opazili zmanjšanje bolečine, ki se je ohranilo ves čas zdravljenja.
The N- methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. 
Na računa N-metiliranega derivata pregabalina, ki je glavni presnovek pregabalina v urinu, je šlo 0,9 % odmerka.
There have also been postmarketing reports of loss of consciousness, confusion and mental impairment. 
V obdobju trženja so poročali tudi o izgubi zavesti, zmedenosti in poslabšanju mentalnih sposobnosti.
See section 4. 
Preglednica 1.
There are no adequate data from the use of pregabalin in pregnant women. 
O uporabi pregabalina pri nosečnicah ni zadostnih podatkov.
Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities. 
Bolnikom je treba svetovati, naj ne vozijo, ne upravljajo zapletenih strojev in ne sodelujejo pri drugih potencialno nevarnih dejavnostih, dokler ni znano, kako to zdravilo vpliva na njihovo zmožnost za takšne dejavnosti.
Tachycardia, atrioventricular block first degree, sinus bradycardia, congestive heart failure 
Tahikardija, atrioventrikularni blok prve stopnje, sinusna bradikardija, kongestivno srčno popuščanje
Adjunctive treatment 
Dodatno zdravljenje
Urinary incontinence, dysuria 
Urinska inkontinenca, dizurija
There are no clinical data on the effects of pregabalin on female fertility. 
Ni kliničnih podatkov o vplivu pregabalina na plodnost pri ženskah.
Pregabalin may have minor or moderate influence on the ability to drive and use machines. 
Pregabalin ima lahko blag ali zmeren vpliv na sposobnost vožnje in upravljanja strojev.
Anorexia, hypoglycaemia 
Anoreksija, hipoglikemija
Stevens-Johnson syndrome, cold sweat Musculoskeletal and connective tissue disorders Common 
Stevens-Johnsonov sindrom, hladen znoj Bolezni mišično-skeletnega sistema in vezivnega tkiva Pogosti
TID = Three divided doses. 
3-krat/dan = tri deljene odmerke
Pregabalin may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. 
Pregabalin lahko povzroči omotico in somnolenco in tako lahko vpliva na sposobnost vožnje in upravljanja strojev.
The 50 mg capsules also contain propylene glycol, strong ammonia solution, potassium hydroxide. 
50 mg kapsule vsebujejo tudi propilen glikol, močno raztopino amoniaka, kalijev hidroksid.
once in the morning, once in the afternoon and once in the evening, at about the same time each day. 
dvakrat na dan, ga vzemite enkrat zjutraj in enkrat zvečer, in sicer vsak dan ob približno istem času.
The other ingredients are lactose monohydrate, pregelatinized maize starch, talc, titanium dioxide (E171), gelatin, shellac, black iron oxide (E172). 
Druge sestavine zdravila so: laktoza monohidrat, pregelirani koruzni škrob, smukec, titanov dioksid (E171), želatina, šelak, črni železov oksid (E172).
• Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, changes in heartbeat, heart failure. 
• motnje srčnega ritma, pospešen srčni utrip, nizek krvni tlak, visok krvni tlak, spremembe srčnega utripa, srčno popuščanje
Median 24-hour seizure frequencies at baseline and at the final visit were 4.7 and 3.8 for pregabalin 7 mg/kg/day, 5.4 and 1.4 for pregabalin 14 mg/kg/day, and 2.9 and 2.3 for placebo, respectively. 
Mediana 24-urna pogostnost napadov je bila ob izhodišču in končnem obisku 4,7 in 3,8 za pregabalin 7 mg/kg/dan, 5,4 in 1,4 za pregabalin 14 mg/kg/dan, ter 2,9 in 2,3 za placebo.
* Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST). 
Zmanjšanje števila levkocitov * zvišanje alanin aminotransferaze (ALT) in aspartat aminotransferaze (AST)
After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed in some patients. 
Po prekinitvi kratkotrajnega in dolgotrajnega zdravljenja s pregabalinom so pri nekaterih bolnikih opazili odtegnitvene simptome.
The pregabalin clinical programme involved over 8,900 patients exposed to pregabalin, of whom over 5,600 were in double-blind placebo controlled trials. 
Klinični program pregabalina je zajel prek 8.900 bolnikov, izpostavljenih temu zdravilu; 5.600 od teh je bilo vključenih v dvojno slepa, s placebom nadzorovana preskušanja.
in addition to your current treatment. 
morate jemati poleg trenutno uporabljanih zdravil.
than you should Call your doctor or go to the nearest hospital emergency unit immediately. 
Če ste vzeli večji odmerek zdravila Pregabalin Zentiva k.s., kot bi smeli Pokličite zdravnika ali nemudoma pojdite v ambulanto za nujno pomoč najbližje bolnišnice.
The pregabalin safety profile observed in four paediatric studies in patients with partial seizures with or without secondary generalisation (12-week efficacy and safety study in patients 4 to 16 years of age, n = 295; 14-day efficacy and safety study in patients 1 month to younger than 4 years of age, n = 175; pharmacokinetic and tolerability study, n = 65; and 1 year open label follow on safety study, n = 54) was similar to that observed in the adult studies of patients with epilepsy. 
Varnostni profil pregabalina, opažen v štirih študijah pri otrocih s parcialnimi napadi s sekundarno generalizacijo ali brez nje (12-tedenska študija učinkovitosti in varnosti pri bolnikih, starih od 4 do 16 let, n = 295; 14-dnevna študija učinkovitosti in varnosti pri bolnikih, starih od 1 meseca do manj kot 4 leta, n = 175; študija farmakokinetike in prenašanja zdravila, n = 65; in enoletna odprta nadaljevalna študija varnosti, n = 54), je bil podoben tistemu v študijah pri odraslih z epilepsijo.
Pregabalin 14 mg/kg/day significantly reduced the log-transformed partial onset seizure frequency versus placebo (p=0.0223); pregabalin 7 mg/kg/day did not show improvement relative to placebo. 
Pregabalin 14 mg/kg/dan je v primerjavi s placebom pomembno zmanjšal logaritemsko pretvorjeno pogostnost parcialnih napadov (p = 0,0223), pregabalin 7 mg/kg/dan pa v primerjavi s placebom ni pokazal izboljšanja.
* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose. 
2-krat/dan = dva deljena odmerka * Celotni dnevni odmerek (mg/dan) je treba razdeliti, kot navaja odmerna shema, da dobimo mg/odmerek.
Capsules content Lactose monohydrate Pregelatinized maize starch Talc 
Vsebina kapsule laktoza monohidrat predgelirani koruzni škrob smukec
Treatment of pregabalin overdose should include general supportive measures and may include haemodialysis if necessary (see section 4.2 table 1). 
Zdravljenje prevelikega odmerjanja pregabalina mora obsegati splošne podporne ukrepe in lahko vključuje hemodializo, če je potrebno (glejte poglavje 4.2, preglednico 1).
Appetite increased 
Zvečanje apetita